Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

GammaDelta Therapeutics Ltd.

GammaDelta Therapeutics (“GammaDelta”) is clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer. Committed to transforming the treatment of patients living with cancer, the Company is developing an ‘off-the-shelf’ therapy based on one of the body’s own immune cells, a subtype of the gamma delta (?d) T-lymphocyte, known as the Vd1+ T cell. The Company has developed proprietary technologies to generate both blood-and tissue-derived allogeneic immunotherapies based on Vd1 ?d T cells for the treatment of hematological malignancies and solid tumors. Both platforms have enabled the creation of non-engineered and genetically engineered allogeneic cell therapies, which demonstrate cellular activity and tumor cell killing capacity in pre-clinical models. GammaDelta is advancing its novel, ?d T cell platforms and product candidates under an ongoing collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). GammaDelta’s technologies are based on pioneering world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute, and Professor Bruno Silva-Santos at the University of Lisbon. Early-stage research was facilitated in part by the support and the infrastructure of the National Institute for Health Research Guy’s and St Thomas’ Biomedical Research Centre. The formation of GammaDelta as a company was supported by Cancer Research UK Commercial Partnerships. GammaDelta’s technologies have attracted significant investment from Takeda and leading life sciences investor, Abingworth LLP. *

 

Period Start 2016-06-17 established
Products Industry T cell therapy
  Industry 2 cancer immunotherapy (immuno-oncology, I-O)
Persons Person Paoletti, Paolo (GammaDelta Therapeutics 201705– CEO before Kesios Therapeutics CEO + GSK)
  Person 2 Haines, Timothy (Tim) (Abingworth 201507– Managing Partner joined 2005 before Astex CEO)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 195 Wood Lane
The Westworks, White City Place
  City W12 7FQ London
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for »About Section«: GammaDelta Therapeutics Ltd.. (10/27/21). "Press Release: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic gdT Cell Therapies Addressing Solid Tumors". Osaka & London.
     
   
Record changed: 2023-07-10

Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Takeda (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Cardiovascular Health in Berlin-Brandenburg 650x300px




» top